India underlines 'robust, balanced' IP regime at WIPO
This article was originally published in Scrip
A senior Indian government minister has underlined to a meeting of the World Intellectual Property Organization that recent pharma-related patent decisions are not the whims of rogue officials or judges but are fully in line with India’s industry and development policies. The clear message to the world’s drug companies is that India will use whatever ‘flexibility’ exists in international intellectual property agreements to help reach its aspirations.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.